Quick Answer
Xeris Biopharma Holdings, Inc. reported Operating Income of $24.90 million for fiscal year 2025.
Xeris Biopharma Holdings, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $24.90M | +174.0% |
| 2024 | -$33.65M | +23.5% |
| 2023 | -$44.01M | +46.3% |
| 2022 | -$81.94M | +28.8% |
| 2021 | -$115.16M | -37.8% |
| 2020 | -$83.55M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.73M | +152.2% | +50.2% |
| June 30, 2025 | $4.48M | +154.7% | +245.0% |
| March 31, 2025 | -$3.09M | +78.3% | +76.0% |
| September 30, 2024 | -$12.89M | -162.4% | -57.5% |
| June 30, 2024 | -$8.19M | +48.8% | +42.5% |
| March 31, 2024 | -$14.24M | -7.3% | -189.9% |
| September 30, 2023 | -$4.91M | +73.8% | +69.3% |
| June 30, 2023 | -$15.98M | +15.5% | -20.4% |
- Xeris Biopharma Holdings, Inc. showed an increase of +174.0% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Xeris Biopharma Holdings, Inc.’s operating income has grown by 129.8% (from -$83.55 million to $24.90 million).
- The most recent figure is from Xeris Biopharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: